Intraperitoneal Cisplatin with Intraperitoneal Gemcitabine in Patients with Epithelial Ovarian Cancer: Results of a Phase I/II Trial Academic Article Article uri icon

Overview

MeSH Major

  • Antigens, Neoplasm
  • Cancer Vaccines
  • Immunotherapy, Adoptive
  • Ovarian Neoplasms

abstract

  • The median time to treatment failure and overall survival of 15.9 months and 43.5 months, respectively, are consistent with our historical data in patients receiving i.p. platinum-based regimens for consolidation. The fibrotic changes seen in explored patients suggest local toxicity of this combination. The absolute benefit of i.p. consolidation requires randomized trials to assess efficacy.

publication date

  • May 2004

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-03-0486

PubMed ID

  • 15131031

Additional Document Info

start page

  • 2962

end page

  • 7

volume

  • 10

number

  • 9